3 results
Approved WMOCompleted
To evaluate the safety, tolerability, PK, PD and efficacy of intravenous (IV) ATB200 alone and when co-administered with oral AT2221.
Approved WMOCompleted
To demonstrate non-inferiority of a T2T strategy in which conventional synthetic disease modifying drugs (csDMARDs) refractory RApatients are initially treated with tsDMARD baricitinib versus the comparable T2T strategy in which patients areā¦
Approved WMORecruiting
To investigate whether enhanced expression of growth factor receptors (FGF-R, PDGF-R and VEGF-R) and increasedvascular cell proliferation in the lung of IPF or PAH patients can be assessed using [11C]-Nintedanib or [18F]-FLTPET/CT imaging.